IBEX Technologies, Inc.

  • Market Cap: Micro Cap
  • Industry: Medical Specialties
  • ISIN: CA4489375085
CAD
1.44
1.44 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About IBEX Technologies, Inc. stock-summary
stock-summary
IBEX Technologies, Inc.
Medical Specialties
IBEX Technologies Inc., through its subsidiaries, IBEX Pharmaceuticals Inc. and BioResearch Products Inc., manufactures and markets enzymes for biomedical use. The Company also manufactures and markets a series of arthritis assays, which enable the study of both the synthesis and degradation of cartilage components. It operates through the production and sale of diagnostic products segment. Its products include IB-C2C-HUSA, C2C Assay, CPII Assay, C1-2C Assay and CS-846 Assay. It provides various individual collagen associated antibodies, such as Ab1320-Rabbit Polyclonal Antibody; Type IX Collagen Antibody, and C1-2C Antibody (Col 2 3/4C short Antibody). Its diagnostic microtiter enzyme-linked immunosorbent assays include C2C-Collagen Type II Cleavage Assay; IB-C2C-HUSA-IBEX C2C Human Urine Sandwich Assay; C1,2C-Collagen Type I and II Cleavage Assay (Col 2 3/4C short antibody); CPII-Procollagen Type II C-Propeptide Assay, and CS846-Aggrecan Chondroitin Sulfate 846 Epitope Assay.
Company Coordinates stock-summary
Company Details
Suite 100, 5485 Pare Street , MONTREAL QC : H4P 1P7
stock-summary
Tel: 1 514 3444004
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Paul Baehr
Chairman of the Board, President, Chief Executive Officer
Mr. Robert DeLuccia
Lead Independent Director
Dr. Bruce Connop
Director
Dr. Joseph Zimmermann
Director
Dr. Thomas Hecht
Independent Director
Mr. Danilo Netto
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Jan 2024)
Net Profit:
0 Million
stock-summary
Industry

Medical Specialties

stock-summary
Market cap

CAD 35 Million (Micro Cap)

stock-summary
P/E

9.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.59

stock-summary
Return on Equity

27.93%

stock-summary
Price to Book

2.48